Time filter

Source Type

Łomianki, Poland

Paczkowska E.,Celon Pharma | Smukowska D.,Celon Pharma | Tratkiewicz E.,Celon Pharma | Bialasiewicz P.,Medical University of Lodz
Acta Chromatographica | Year: 2015

A simple and accurate reversed phase high-performance liquid chromatography (HPLC) method has been developed for the estimation of uniformity of dosage units, and delivered dose uniformity tests of fluticasone propionate and salmeterol xinafoate in samples obtained during the fine particle mass determination, using C8 Luna (2) 100A 100 x 4.6 mm, 5 micrometer particle size in gradient mode, with mobile phase comprising of buffer solution: 0.6% trifluoroacetic acid solution in water- Tetrahydrofurane (8:2 v/v) and acetonitrile-methanol (1:1 v/v) in the ratio of 60:40 v/v. The flow rate was 1.5 mL min-1, and the detection was monitored by ultraviolet (UV) detector at 239 nm and 250 nm. Linearity was observed in the concentration range of 0.025- 4.8μg mL-1 for salmeterol xinafoate and 0.04-32.5 μg mL-1 for fluticasone propionate (R2 > 0.999). The recovery in the range from 98.2% to 102.7% and relative standard deviation (RSD) ≤ 2.2% demonstrated accuracy and high precision of the method. The quantification limit at an injection volume of 40 μL was 0.04 μg mL-1 for fluticasone propionate and 0.025 μg mL-1 for salmeterol xinafoate. The developed and validated method can be successfully applied for simultaneous quality control of dry powder inhalation products containing salmeterol xinafoate and fluticasone propionate in pharmaceutical industry. Source

Mazur M.,Celon Pharma | Mazur M.,Medical University of Lodz | Bujak A.,Celon Pharma | Matloka M.,Celon Pharma | And 9 more authors.
Analytical Biochemistry | Year: 2015

Deregulation of the Wnt/β-catenin signaling pathway is associated with many serious disorders, including cancer and Alzheimer's disease. The pivotal player is β-catenin, which avoids degradation after activation of the pathway and is translocated to the nucleus, where it interacts with TCF/LEF transcription factors and induces expression of genes involved in cell cycle and apoptosis regulation. The identification of small molecules that may affect Wnt/β-catenin signaling remains an important target during the development of novel therapies. We used the TCF/LEF lentiviral vector and the Wnt-independent H1703 cell line to develop a luciferase reporter-based cell assay for screening of the Wnt/β-catenin pathway modulators. Following the optimization of cell density, concentration of activator, and stimulation time, the reporter system was validated by demonstrating its specific and dose-dependent response to several established modulators of Wnt/β-catenin signaling such as Wnt3a, small interfering RNA (siRNA) against β-catenin, glycogen synthase kinase 3 (GSK-3), and β-catenin/TCF transcription complex inhibitors. Two pilot screens of inhibitors and activators of Wnt/β-catenin signaling identified potential novel modulators of this pathway. Our findings suggest that the H1703-7TFP assay constitutes a suitable model of low background and high sensitivity for the low- and high-scale screening of the Wnt/β-catenin pathway modulators. © 2015 Elsevier Inc. All rights reserved. Source

Discover hidden collaborations